NCT05952388

Brief Summary

The purpose of this study is to evaluate the effects of pharmaceutical care interventions in the ambulatory hemodialysis patients over a one-year period. Cost containment occurs through pharmaceutical care interventions designed to identify and ameliorate drug-related problems (DRPs), improve the cost-effectiveness of therapeutic regimens and prevent hospitalizations.

Trial Health

15
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Jan 2003

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2003

Completed
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2003

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2003

Completed
5.5 years until next milestone

First Submitted

Initial submission to the registry

July 9, 2008

Completed
15 years until next milestone

First Posted

Study publicly available on registry

July 19, 2023

Completed
Last Updated

March 13, 2024

Status Verified

March 1, 2024

Enrollment Period

Same day

First QC Date

July 9, 2008

Last Update Submit

March 11, 2024

Conditions

End Stage Renal Disease

Keywords

Document the number, type, and severity of DRPsin HD patients.Determine the rates and categorization ofDRPs-associated hospitalizations in HD patients.Document the number and types of pharmaceuticalCare Interventions.Determine the outcomes of pharmaceutical careInterventionDetermine the rate of acceptance of pharmaceuticalCare Interventions .Assign significance rank to pharmaceuticalDetermine annual drug cost in HD patients.Determine drug cost associated for treatmentof each HD patient comorbidity.Determine Quality of Life (QoL) using a renal-specific instrument

Outcome Measures

Primary Outcomes (1)

  • Reduction in at home medications

    Behavioral: Patent care

    through study completion, an average of 1 year

Study Arms (1)

Behavioral Patient Care

NO INTERVENTION

Chart review

Other: Behavioral Patient care

Interventions

Behavioral Patient careOTHER

chart review

Also known as: Chart review
Behavioral Patient Care

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may not qualify if:

  • Patients will be excluded if they have been on HD for less than three months, decline the opportunity to participate, or are less than 18 years of age.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Kidney Failure, ChronicLimb-girdle muscular dystrophy, type 2C

Condition Hierarchy (Ancestors)

Renal Insufficiency, ChronicRenal InsufficiencyKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Amy B Pai, Pharm.D

    University of New Mexico

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 9, 2008

First Posted

July 19, 2023

Study Start

January 1, 2003

Primary Completion

January 1, 2003

Study Completion

January 1, 2003

Last Updated

March 13, 2024

Record last verified: 2024-03